Analyst firms · Leerink Partners · AMYT
Leerink Partners AMYT price target and rating history
Amryt Pharma plc (AMYT) · Health Care
Leerink Partners rates Amryt Pharma plc (AMYT) Outperform with a $10 price target, as of its latest action on Mar 10, 2022. It has published 3 rating actions on AMYT since August 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Outperform
- Price target
- $10
- Median target, all firms
- Too few
- Actions on AMYT
- 3
Leerink Partners price target on AMYT
Every Leerink Partners rating on AMYT
- Mar 10, 2022
- Nov 23, 2021
- Aug 19, 2021
Questions about Leerink Partners and AMYT
- What is Leerink Partners's price target for AMYT?
- Leerink Partners's latest stated price target for Amryt Pharma plc (AMYT) is $10, from its action on Mar 10, 2022.
- What is Leerink Partners's rating on AMYT?
- Leerink Partners rates AMYT Outperform, a bullish rating, as of Mar 10, 2022.
- When did Leerink Partners last change its view on AMYT?
- On Mar 10, 2022, Leerink Partners raises its price target to $10 from $9, keeps Outperform.
All Leerink Partners ratingsAMYT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.